Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

Publication date

2024-11

Authors

Amaador, Karima
Thieblemont, Catherine
Trotman, Judith
Minnema, Monique C.ORCID 0000-0002-3139-8379ISNI 0000000394782842

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.

Keywords

marginal zone lymphoma, treatment, Waldenstrom macroglobulinemia, Hematology, Oncology, Cancer Research, Review, Journal Article

Citation

Amaador, K, Thieblemont, C, Trotman, J & Minnema, M C 2024, 'Recent updates in the indolent lymphomas : Update on marginal zone lymphoma and Waldenström's macroglobulinemia', Hematological Oncology, vol. 42, no. 6, e3210. https://doi.org/10.1002/hon.3210